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Abstract
Introduction The introduction of high-throughput technologies,
also called -omics technologies, into epidemiology has raised
the need for high-quality observational studies to reduce several
sources of error and bias.
Methods The Norwegian Women and Cancer (NOWAC)
postgenome cohort study consists of approximately 50,000
women born between 1943 and 1957 who gave blood samples
between 2003 and 2006 and filled out a two-page
questionnaire. Blood was collected in such a way that RNA is
preserved and can be used for gene expression analyses. The
women are part of the NOWAC study consisting of 172,471
women 30 to 70 years of age at recruitment from 1991 to 2006
who answered one to three questionnaires on diet, medication
use, and lifestyle. In collaboration with the Norwegian Breast
Cancer Group, every NOWAC participant born between 1943
and 1957 who is admitted to a collaborating hospital for a
diagnostic biopsy or for surgery of breast cancer will be asked
to donate a tumor biopsy and two blood samples. In parallel, at
least three controls are approached for each breast cancer case
in order to obtain blood samples from at least two controls per
case. The controls are drawn at random from NOWAC matched
by time of follow-up and age. In addition, 400 normal breast
tissues as well as blood samples will be collected among
healthy women participating at the Norwegian Mammography
Screening program at the Breast Imaging Center at the
University Hospital of North-Norway, Tromsø.
Results The NOWAC postgenome cohort offers a unique
opportunity (a) to study blood-derived gene expression profiles
as a diagnostic test for breast cancer in a nested case-control
design with adjustment for confounding factors related to
different exposures, (b) to improve the reliability and accuracy of
this approach by adjusting for an individual's genotype (for
example, variants in genes coding for hormone and drug-
metabolizing and detoxifying enzymes), (c) to study gene
expression profiles from peripheral blood as surrogate tissue to
biomonitor defined exposure (for example, hormone) and its
association with disease risk (that is, breast cancer), and (d) to
study gene variants (single nucleotide polymorphisms and copy
number variations) and environmental exposure (endogenous
and exogenous hormones) and their influence on the incidence
of different molecular subtypes of breast cancer.
Conclusion The NOWAC postgenome cohort combining a
valid epidemiological approach with richness of biological
samples should make an important contribution to the study of
the etiology and system biology of breast cancer.
Introduction
Observational epidemiologic data are used as major criteria to
categorize any chemicals or lifestyle factors as carcinogenic.
This is an inherent part of the carcinogen classification as car-
ried out by the World Health Organization through its cancer
research center at the International Agency for Research on
Cancer in Lyon, France [1]. The burden of cancer still
increases and the term 'human carcinogen' is important for
cancer prevention since it forms much of the basis for public
health initiatives like programs for stopping the smoking epi-
demic, advice about medication use, and workplace safety.
CNV = copy number variation; DCIS = ductal carcinoma in situ; GWA = genome-wide association; HT = hormone therapy; NOWAC = Norwegian 
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At first, a prospective cohort study consisted of exposure infor-
mation given by questionnaires and participant follow-up,
either passive through different registers or active by repeated
interviews. Collection of biological samples, mainly from
peripheral blood, for exposure or biomarker measurements
became part of many epidemiological research designs in the
1970s. Plasma and serum can be used to study proteins and
metabolites, and with recent large-scale approaches, the total
proteome and metabolome can be analyzed. In addition, the
availability of germline DNA gives the opportunity for genotyp-
ing, followed by gene-environment and gene-gene interaction
studies. Today, hundreds of thousands of probes spotted
either on a glass slide or on beads allow whole-genome scans
of single nucleotide polymorphisms (SNPs) and copy number
variations (CNVs) for each individual. About a decade ago,
new inventions opened up a third level of studies investigating
gene expression at the RNA level from peripheral blood and
tumor tissue by microarray technology. It should be noted that,
due to the effect of RNases, which degrade RNA unless sta-
bilized into a specific buffer, standard biobanks do not provide
high-quality mRNA.
The introduction of high-throughput technologies, also called
-omics technologies, into epidemiology has raised the need for
high-quality observational studies to reduce several sources of
error and bias [2,3]. This is related to the selection of study
populations, technical challenges, and the necessary size of
the studies. To overcome some of these challenges and to be
able to take full advantage of the new technologies, the Nor-
wegian Women and Cancer (NOWAC) postgenome cohort
study was created with a biobank that gives the possibilities
for RNA and DNA whole-genome scans of both peripheral
blood and breast tissue. Here, we present the unique design
of the NOWAC postgenome cohort which will enable us to
fully investigate all aspects of the relationship between expo-
sures and breast cancer by giving us the opportunity to look at
genetic predisposition (CNVs or SNPs), gene expression
(RNA and microRNA), gene products (proteome) and their
metabolites (metabolome), and information given by question-
naire in relation to breast cancer risk, stratified by molecular
markers of tumor subtypes.
Materials and methods
The NOWAC postgenome cohort consists of approximately
50,000 women born between 1943 and 1957 who gave
blood samples between 2003 and 2006 (Figure 1). The
women are part of the NOWAC study consisting of 172,471
women 30 to 70 years of age at recruitment from 1991 to
2006 ([4] and Figure 1 of [5]). Of the 172,471 women partic-
ipating today, 148,536 were born between 1943 and 1957.
The whole cohort consists of random samples from all coun-
ties in Norway, but in Northern Norway (three counties), Roga-
land, and Oslo, all women in this age range were invited to
participate. The overall response rate is close to 72.3%. It
decreases slightly with age and varies by region with a higher
response rate in North-Norway [6]. The participants have
answered one to three four-page questionnaires of core varia-
bles: use of hormonal treatments, reproductive history, ages at
menarche and menopause, smoking, physical activity, alcohol
consumption, anthropometry, socioeconomic status, screen-
ing for breast cancer, breast cancer in the family, sunbathing
habits and pigmentation, and self-reported diseases. A major
part of the questionnaires has, in addition, four pages asking
for detailed information on dietary habits. In the introduction
letter, they were informed that they could be asked for a blood
donation. Notably, BRCA (Breast Cancer gene) status was
not specifically asked for but family history for breast cancer
was provided by questionnaire as listed above. In the clinic,
women with strong family history are referred for counselling
to cancer genetic specialists by their local physician.
Women included in the postgenome NOWAC study were
sampled at random from the whole cohort in series of 500
women each. Each woman received a package with an infor-
mation folder explaining the purpose of the study with the spe-
cific items related to the informed consent. The women were
asked to visit their family doctor or any other authorized place
for blood drawing and to take with them the necessary equip-
ment that they had received: a special glass tube for conser-
vation of mRNA in a buffer (PAXgene™ Blood RNA System;
PreAnalytiX GmbH, Hombrechtikon, Switzerland), a glass
tube with citrate, needles, and a prepaid envelope for high-pri-
ority post for shipping the biological samples. At the time of
blood sampling, they had to fill out a two-page questionnaire
with information on current use of hormonal treatments and
other pharmaceutical therapeutics (over-the-counter and pre-
scription), dietary supplements, smoking, and height and
weight. The blood samples then were sent by overnight mail to
the Institute of Community Medicine at the University of
Tromsø, Norway. On arrival, the citrate glass tube was centri-
fuged and 'buffy-coated' and two tubes of plasma were frozen
at -80°C. The PAXgene™ tubes were frozen directly at -80°C
as recommended by the manufacturer.
Passive follow-up
Information on cancer cases among NOWAC postgenome
cohort members is sought by yearly linkage to the Norwegian
Cancer Register based on the unique person number [7] (so
far, until the end of 2005). As of 31 December 2005, there
were 2,237 incident breast cancer cases among the first
102,410 women included in NOWAC. The Norwegian Can-
cer Register is building a nationwide database reporting treat-
ment and follow-up information for breast cancer. Possible
linkage to the cancer register database is indicated in the
informed consent form, but approval from the ethical commit-
tee to do this linkage is a prerequisite.Available online http://breast-cancer-research.com/content/10/1/R13
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Active follow-up: blood and breast tissue collection from 
cases and controls
Norway has around 436,338 women born between 1943 and
1957 [8], of whom 148,536 (34.4%) participate in NOWAC.
At present, 11 of the largest Norwegian hospitals participate
in collecting blood and tumor tissue from incident breast can-
cer cases. In collaboration with the Norwegian Breast Cancer
Group, every woman born between 1943 and 1957 who is
admitted to a collaborating hospital for a diagnostic biopsy or
for surgery of breast cancer will be asked whether she partic-
ipates in the NOWAC study. If she answers yes, she will be
asked to donate a tumor biopsy collected in RNALater and two
blood samples, one collected into PAXgene™ and another in a
citrate tube for RNA, DNA, protein, and metabolite analyses
(Figure 1). RNALater provides a simple, safe, and effective
method for prospectively acquiring and processing breast
core needle biopsies for gene expression studies [9]. If she
does not remember her earlier participation in NOWAC, infor-
mation is sought in the NOWAC files based on name and birth
year. NOWAC participants then are asked to sign a new
informed consent form and to answer a short questionnaire
eliciting information mainly on use of medications. In the same
manner as in the postgenome cohort, biological samples are
mailed overnight to Tromsø.
In parallel, at least three controls are approached for each
breast cancer case in order to obtain blood samples from at
least two controls per case. The controls are drawn at random
from the same original series but matched by time of follow-up
and age. During the first 8 months of active follow-up, we
received 73 biological samples from incident breast cancer
cases or an estimated number of 110 per year.
The Norwegian Breast Cancer Screening program invites all
women 50 to 69 years of age to mammography every second
year. The period of the next 6 years of the NOWAC cohort
fairly corresponds to the screening cohort and this gives an
opportunity to collect breast tissue from controls among the
participants in NOWAC. The aim is to collect 400 samples of
normal breast tissue as well as blood samples among healthy
women participating in the Norwegian Mammography Screen-
ing program at the Breast Imaging Center at the University
Hospital of North-Norway, Tromsø (Figure 1). The women are
asked to sign an informed consent form and to answer the
same questionnaires as the cases. The tissue and blood sam-
ples are managed in the same manner as the cases. So far,
about 60 tissue samples have been collected. It is planned to
collect 10 samples a week.
Figure 1
Study design of the Norwegian Women and Cancer (NOWAC) postgenome cohort study Study design of the Norwegian Women and Cancer (NOWAC) postgenome cohort study.Breast Cancer Research    Vol 10 No 1    Dumeaux et al.
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Validity
The external validity of NOWAC as a representative sample of
the Norwegian female population has been verified in several
methodological analyses and found to be acceptable [6].
Studies of the internal validity, including reliability, have been
undertaken for the dietary questions [10-12], menopausal sta-
tus, and use of hormonal replacement therapy [13], whereas
validation of physical activity is ongoing.
Biobank and database
The Medical Faculty at the University of Tromsø is responsible
for the maintenance of the biobank with quality and security
control. The data are held by the NOWAC research team at
the Institute of Community Medicine, Medical Faculty, Univer-
sity of Tromsø, Norway. The University of Tromsø has the legal
rights to this database.
Ethical issues
We have received approval from the Regional Committee for
Medical Research Ethics for the collection and storing of
questionnaire information, blood samples, and tumor tissue.
All women have filled out an informed consent form for later
linkages to national registers. The informed consent formula
explicitly mentions that the blood samples can be used for
gene expression analyses as well as large-scale genotyping.
All data are stored and handled according to the permission
given by the Norwegian Data Inspectorate. The Directorate of
Health and Social affairs (SHD) has given us an exemption
from the confidentiality of information in national registers.
Before every use of the biological material, a request will be
sent to the regional ethical committee for Northern-Norway.
Use of biological material requires permission according to
laws pertaining to biotechnology and gene technology, both of
which are administered by the SHD.
Improvement in technology and analysis
Globin RNA processing methods for genome-wide 
transcriptome analysis from whole blood
The use of the PAXgene™ Blood RNA System offers advan-
tages for the shipping of blood samples by direct preservation
of RNA. However, excess globin mRNA originating mainly from
lysed immature reticulocytes in the stabilized samples has
been shown to adversely impact gene expression profiling
using microarrays [14]. In a pilot study, we assessed whether
RNA from whole blood with or without globin reduction gives
the most robust and sensitive results to detect small gene
expression changes in response to hormone therapy (HT)
exposure [15]. Overall, no sign of higher sensitivity in the
detection of gene expression changes using the Applied Bio-
systems Microarray System (Applied Biosystems, Foster City,
CA, USA) was observed after globin reduction, although in
previous studies using Affymetrix GeneChip arrays (Affymetrix,
Santa Clara, CA, USA), it appeared to be beneficial [16-20].
We concluded from this that the appropriate RNA processing
method should be chosen according to the microarray plat-
form to be used. However, this will pose a problem regarding
standardization of the methods since globin-reduced and non-
globin-reduced approaches produce distinct gene expression
profiles which are not directly comparable [15,19].
White blood cells have been defined as the most transcription-
ally active cells in blood and may give the most sensitive gene
expression profiles in response to defined factors [21]. How-
ever, a PAXgene™ tube with relative compromised sensitivity
for global gene expression profiling, but with the advantage of
stabilizing RNA in such a large-scale study, may be suitable to
study some exposure or health status. For others, it may be
beneficial to perform additional fractionation in a nested case-
control design to isolate only the cells belonging to a subtype.
Choice of microarray platform
In our exploratory research investigating blood gene expres-
sion profiles according to hormone exposure in women [22],
we initially used the Human 1A oligo arrays (22K) produced by
Agilent Technologies, Inc. (Santa Clara, CA, USA). This two-
color array platform required cohybridization of a sample and
a standard reference, so the relative expression level for each
individual gene can be readily normalized and related across
multiple experiments. The commercially available Universal
Human Reference RNA from Stratagene (La Jolla, CA, USA)
[23] is designed to provide a baseline measurement of every
gene, although this common reference does not have any bio-
logical meaning. We also encountered hybridization problems
with Cy5 dye degradation due to the presence of ozone [24].
After a special washing step with a stabilization and drying
solution recommended by the producer, red and green aver-
age signals were approximately at the same level, but with
lower mean intensity (V. Dumeaux, A-L. Børresen-Dale, E.
Lund, unpublished data). To be noted, Agilent Technologies,
Inc., has developed a new dual-channel workflow as well as a
one-channel protocol option that are supposed to overcome
some of these issues.
In our following study, we used the Applied Biosystems
Human Genome Survey oligo-microarray platform, a one-color
system based on chemiluminescence [15]. The results were
satisfying and indicated that smaller variations were reliably
detected. However, the throughput of the Applied Biosystems
platform is rather low and therefore not ideal for large-scale
epidemiological studies. The bead array system produced by
Illumina, Inc. (San Diego, CA, USA) seems to be a cost-effec-
tive alternative, hopefully as sensitive and reliable without the
need for globin reduction, but this should be evaluated before
conducting blood gene expression analyses in future studies
of the NOWAC cohort.Available online http://breast-cancer-research.com/content/10/1/R13
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Research designs
1. Blood-derived gene expression profiles as diagnostic test 
for breast cancer adjusted for exposure confounder effect
Mammography is by far the most commonly used method for
early detection of breast cancer in women 50 to 69 years of
age. However, the sensitivity, specificity, and cost of mammog-
raphy screening have been debated for many years. Tumors
less than 5 mm in size are, in general, difficult to detect by
mammography, and some types of breast cancer like lobular
cancer are often missed. In addition, it is difficult to interpret
mammograms from women with dense breast tissue, a com-
mon feature of younger women [25,26]. Also, some tumors
may develop too rapidly to be identified at the most treatable
stage by mammography screening every second year [27].
Many women are also diagnosed with in situ cancer (ductal
carcinoma in situ, DCIS), and it is widely discussed whether
all women with DCIS will develop a malignant tumor and
whether too many are unnecessarily treated. Finally, sensitivity
of the mammography screening is comparatively high (>75%)
while spontaneous regression of many subclinical cancerous
tumors may not be uncommon [28]. This is important because
the effects of overdiagnosis extend beyond living with the
diagnosis of cancer and include adverse effects of treatment
for breast cancer (surgery, endocrine therapy, chemotherapy,
and radiotherapy).
There is a growing evidence that by analyzing the changes in
gene activity in sensor cells (like blood cells), it might be pos-
sible to provide information on whether tumor cells are present
elsewhere in the body (for instance, in the breast). Some stud-
ies have found that the use of peripheral blood cells for tran-
scriptome analysis was valuable in assessing disease-
associated [29-33] and drug-response-related [34] gene sig-
natures. The search for gene expression profiles in blood-
based tests for early diagnosis of breast cancer as an added
test in relation to mammographic screening is ongoing based
on case-control design and using women with dense mammo-
grams as controls [33]. If a dense mammogram is part of the
causal chain of breast cancer, the use of such controls may
reduce the sensitivity of the test because controls could
express genes partly as a result of an early carcinogenic proc-
ess. On the other hand, the signatures developed using such
controls may help identify cancer cases in the group of women
with uncertain mammograms.
Adjusting the analysis of gene expression profiles for con-
founders may increase the sensitivity of the diagnostic profile
since exposure risk factors for breast cancer could partly
explain the expression of genes in the cases. In the NOWAC
cohort, current users of HT had a twofold increase in breast
cancer risk compared with never users [35] and small
changes in blood-derived gene expression profiles for HT
users were observed compared with non-HT users [22]. Thus,
gene expression changes in a diagnostic test for breast can-
cer without adjustment for HT use could be due, at least partly,
to different prevalences of HT use among cases and controls.
In this way, the NOWAC postgenome cohort offers a unique
opportunity to study blood-derived gene expression profiles as
a diagnostic test for breast cancer in a nested case-control
design with adjustment for confounding factors related to dif-
ferent exposures. In addition, given the prospective design of
the study with blood sampling prior to diagnosis, blood gene
expression profiles can also be studied as a risk predictor for
breast cancer.
2. Influences of an individual's genotype on breast cancer 
risk
Gene expression changes adjusted for environmental expo-
sure may be insufficient to make an accurate diagnosis or pre-
diction. Breast cancer, like all types of cancer, is considered to
be a genetic disease in the sense that both germline and
somatic mutations may be the cause of tumor initiation and
tumor development. Genetic determinants (for example, vari-
ants in genes coding for hormone and drug-metabolizing and
detoxifying enzymes) may need to be incorporated to improve
the reliability and accuracy of these approaches. New technol-
ogies allow whole-genome scans in unrelated cases and con-
trols in genome-wide association (GWA) studies in the search
for common genetic variants associated with disease risk.
Recently, by means of this approach, novel variants in five
genes were found to slightly increase susceptibility to breast
cancer [36,37]. The increased risks associated with these
alleles are relatively small, but, on the other hand, these sus-
ceptibility alleles are very common (for example, approximately
14% of the UK population are homozygous for the risk allele of
the SNP rs2981582 in FGFR2). Thus, other mutations that
contribute similarly to breast cancer susceptibility may be
found using GWA studies. As additional susceptibility alleles
are identified, a combination of such alleles together with other
breast cancer risk factors may be relevant to implement into
clinical practice.
Although there is little doubt that the novel susceptibility mark-
ers produced from such highly powered studies are true, the
mechanism by which they cause the susceptibility remains
unravelled. SNPs in the recently discovered susceptibility
genes may also exert their effect through the expression of
their genes in tumors, giving rise to the various breast cancer
molecular subtypes [38]. Below in section 4, we further dis-
cuss how the NOWAC postgenome cohort gives a unique
opportunity to stratify patients by their tumor molecular sub-
types, which may give more power to the classical case-con-
trol studies to identify genes of no or borderline significance
for breast cancer as such, but which may be more highly pen-
etrant for certain subclasses.
A strong influence of SNPs in master regulator genes on gene
expression in tumors has already been detected [39], and the
NOWAC study will give us the opportunity to explore the SNP
effect on gene expression in blood and tissue in both healthyBreast Cancer Research    Vol 10 No 1    Dumeaux et al.
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and disease states. In an exploratory approach, whole-genome
SNPs scans that cover more than 100,000 SNPs (100 K Illu-
mina array) have been conducted for the NOWAC women
used in our pilot study for HT profiling [22] in order to explore
the effect of SNP profiles on blood gene expression in both HT
users and nonusers.
3. Blood as surrogate tissue to conduct gene expression 
profiles
The ability to investigate the biological mechanisms and obtain
diagnostic and prognostic information about a target tissue
(for example, breast tissue) by using easily accessible surro-
gate tissues and fluids (for example, blood) has significant and
far-reaching implications for basic and clinical research. Sur-
rogate analysis is not a new concept, but the development of
-omic technologies has broadened both the range of tissues
that can be examined and the number of targets that can be
analyzed in a single experiment. One of the greatest chal-
lenges is the interpretation and appropriate use of all -omic
data obtained from target and surrogate tissues.
We hypothesized that gene expression changes in blood
caused by different exposure and combined with an individ-
ual's genotype could be used prospectively to identify an ele-
vated breast cancer risk. Also, gene expression profiles
associated with a disease state may become apparent in such
prospective studies. This can provide potential gene markers
of susceptibility and response to exposure which can be used
for preventive strategies or could be of potential mechanistic
interest. Ideal genomic biomarkers for exposure would be RNA
species with wide dynamic range, which increased or
decreased in expression in surrogate tissues proportionally to
the dose level.
Blood is currently the most practical choice for surrogate tis-
sue. The relationship between gene expression in target (that
is, breast) and surrogate (that is, blood) tissues, however, must
be better established. Results from Rockett and colleagues
[40] have demonstrated that in rats many genes are coex-
pressed in peripheral blood cells and the uterus. Although
alterations in transcriptional profiles of peripheral blood of
patients with cancer may not share the same identity with
those observed in the primary tumor, such patterns nonethe-
less would be of tremendous physiological relevance and bear
obvious diagnostic value in the assessment of this disease. In
the NOWAC study, questionnaires about exposure (in partic-
ular, hormone exposure), blood, and breast tissue biopsy from
both healthy women and breast cancer cases offer a unique
opportunity to investigate these critical questions.
4. Genetic and environmental influences on the incidence of 
different molecular subtypes of breast cancer
Breast cancer is a heterogeneous disease, and it is likely that
different risk factors and susceptibility factors give rise to dif-
ferent types of breast cancer. Gene expression profiles have
the power of capturing the complexities of tumors and can be
used to portray a tumor's detailed phenotype in its unique con-
text as a basis for an improved diagnostic description or a new
molecular taxonomy of breast cancer [41]. Tumors now can be
grouped according to their expression profiles, and the influ-
ence of gene variants (SNPs and CNVs) and environmental
exposure (endogenous and exogenous hormones) on the
development of different expression 'motifs' of breast cancer
can be studied [42]. Thus, low-penetrant breast cancer gene
variants and gene-environment interactions that are otherwise
difficult to identify in classical case-control studies may appear
to be more highly penetrant for certain subclasses and there-
fore identifiable. Finding susceptibility loci may assist us also
in establishing the causes of different molecular subtypes.
It is critical to use common criteria for molecular profiling of
tumors to avoid the daunting problem of differences caused by
artifacts. Five subtypes of breast tumors characterized by spe-
cific expression patterns using hierarchical clustering
[41,43,44] were associated with significant differences in
overall and relapse-free survival and have been found repeat-
edly in other expression data sets showing the robustness of
this classification [43,45].
Similarly, to elucidate gene-environment interactions, the avail-
ability of accurate data pertaining to environmental influences
is critical. This permits the investigation of the underlying
mechanisms of cancer as the basis for developing new strate-
gies for the intervention or prevention of cancer. Similarly,
gene-gene interactions may play an important role in cancer
susceptibility. Recent work suggests that, when gene-environ-
ment or gene-gene interactions exist, accounting for these in
the whole-genome analysis will improve the probability of
retaining causal loci in the second and subsequent stages of
multistage designs [46].
Discussion
The perspective of the postgenome NOWAC cohort is to
merge a new research field to epidemiology by adding gene
expression profiles both from peripheral blood and tumor tis-
sue to the prospective design, in our case restricted to breast
cancer and healthy controls. Uncertainty remains about the
use of gene expression profiles from peripheral blood as sur-
rogate tissue to biomonitor defined exposure (that is, hor-
mone) and its association with disease risk (that is, breast
cancer). However, we believe that gene expression profiling in
human populations could assist us in (a) measuring exposition
and defining outcome, (b) understanding mode of action, (c)
understanding the etiology of environmentally induced dis-
ease, and (d) improving risk assessment methods and models.
Misclassification of exposure and outcome is an important
source of bias in epidemiologic studies, and most study
designs provide little opportunity to focus on biological mech-
anisms underlying the exposure-disease relationship. GeneAvailable online http://breast-cancer-research.com/content/10/1/R13
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expression profiling provides an opportunity to move beyond
traditional approaches to exposure assessment (for example,
environmental studies based on one chemical agent at a time)
and to outcome assessment (for example, histological type in
cancer). This comprehensive view of exposure and outcome is
needed to define complex exposure-disease relationships and
the interactions between genetic and environmental factors in
human disease.
Genetic markers of disease susceptibility can influence expo-
sure effects and therefore are important to consider in risk
assessments. However, these markers may offer both promise
and peril for individual and population risk assessments. The
promise is for a more refined assessment of risk through the
identification of gene-gene and gene-environment interactions
and also for focusing on prevention and control programs for
high-risk individuals. The perils include ethical and social
issues, including stigmatization and discrimination. One mis-
conception is to believe that removing a susceptible individual
from the exposure without reducing exposure opportunities
reduces risk, whereas this may not be so since polymorphisms
in low-penetrant genes often require exposure to environmen-
tal factors to be effective, meaning that the effect is attributa-
ble to the gene-environment interaction, not to the genetic trait
itself [47].
Due to the huge number of genotyped SNPs, genome-wide
scans are faced with a major statistical problem even when a
single underlying biological hypothesis is being tested. Thus,
sample availability and current genotyping costs almost cer-
tainly will limit the first genome-wide scans to detect main
effects under the hypothesis that a single etiologic entity is
involved [48]. However, each cancer may represent multiple
tumor types within a single histopathologic entity and it will be
critical to use common criteria for molecular profiling of tumors
to avoid the problem of differences caused by artifacts in
expression profiling [48]. Thus, although there is still work to
be done to identify robust molecularly defined subtypes for
tumors at most sites, the availability of tissues in which to strat-
ify subtypes by molecular markers is a valuable adjunct to ini-
tial scans. One purpose of NOWAC was to create a large
prospective cohort in order to collect the necessary number of
cases required for subtype-specific hypotheses. The implica-
tions of these findings for cancer prevention, detection, and
treatment, and whether all this information will lead to actiona-
ble strategies, are unclear. However, we can hope that identi-
fying genes in biological pathways will give us important
information in cancer causation.
The use of a matched nested case-control design in a large
prospective representative cohort will reduce the possible del-
eterious effect of differential recall bias for the exposure infor-
mation and possible systematic errors of selection bias. Most
other studies have not collected cases and controls from the
same study base, which is very important for the validity of the
comparison between cases and controls. The controls should
reflect the exposure levels in the population in which the cases
appear.
Conclusion
The NOWAC postgenome cohort was designed for research
in functional genomics. The combination of a valid epidemio-
logical approach together with richness of biological samples
should make an important contribution to the study of the sys-
tem biology of breast cancer.
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